Margin defense & downside — the aggressive number, stress-tested
The margin is earned, not assumed
REV's most aggressive figures — a ~78% gross margin and a ~65% run-rate EBITDA margin — are not switched on at launch. They are earned over a multi-year ramp as the self-learning system captures more of every encounter. This page shows the real ramp from the proforma, proves the returns stay excellent even if we miss by a lot, and explains why REV beats athenahealth on primary care alone.
Every number on this page is the independent primary-care (PCP) case — 1–5 clinician practices running routine established-patient E/M (the 99213/99214-dominated visit mix). Specialists and non-ambulatory settings look different — usually lower margin and more coding complexity. REV wins primary care first; specialty and enterprise expansion is upside, not assumed.
The ramp — how the margin is actually built
Straight from the proforma's month-by-month series. Gross margin climbs from ~29% to ~78% and EBITDA margin from break-even to ~65% over roughly five years — not a flat assumption. The shaded area is monthly revenue (right axis), which compounds as practices onboard and each provider ramps from Year 1 (~$750K collections) toward the $1,071,000 at-scale level.
We have a couple of years to ramp. Capture and margin compound as the model learns from every encounter — coding accuracy, denial recovery and AR all improve with volume, so the steady-state ~78% gross margin is a destination the system grows into, not a switch flipped on day one. Early months show negative gross margin only because a fixed cost-to-serve base is absorbed against tiny initial revenue; it inverts quickly as providers onboard.
Collections / provider — Year 1
Collections / provider — at scale
Gross margin — Year 2 → Year 5
Capture rate at scale
Ramp basis: the model applies a Year-1 ramp factor of 0.70 to per-provider collections ($1,071,000 × 0.70 ≈ $749,700), with practices onboarding continuously thereafter. Margin figures are computed directly from the monthly proforma series (gross profit ÷ revenue; EBITDA ÷ revenue).
Why ~78% is defensible for primary care
The fair comparison is athenahealth — the scaled, public incumbent — but on the same metric. Athena ran a ~54% non-GAAP gross margin and, on the line that's actually apples-to-apples with ours, a ~29% adjusted (non-GAAP) EBITDA margin in 2018. Its headline GAAP operating margin was only mid-teens, but that's after stock comp, executive pay, heavy S&M and R&D, D&A and public-company overhead — so it understates the real economics. Even measured against athena's ~29% adjusted EBITDA, REV runs higher because it's built paperless, cashless and AI-native for one narrow, repeatable visit mix — it should beat athena on primary-care economics alone. (REV's ~65% is likewise a run-rate, at-scale EBITDA, before financing and taxes.)
| Dimension | athenahealth (incumbent) | REV (PCP-native) |
|---|---|---|
| Gross margin | ~54% non-GAAP (FY2018) | ~78% (PCP, at scale) |
| Adjusted EBITDA margin | ~29% non-GAAP (FY2018) | ~65% run-rate (at scale) |
| GAAP operating margin | mid-teens (after SBC, exec comp, S&M/R&D, D&A) | n/a (pre-GAAP) |
| Scope | Broad, multi-specialty platform | Independent primary care only |
| RCM model | Large human RCM / billing workforce | Automated; clean claims + auto denials/appeals |
| Documentation / coding | Templating + post-visit rework | Ambient AI scribe; coded correctly at the visit |
| Accuracy over time | Rules-based; static | Learns from every encounter (compounding) |
| RCM cost-to-serve | Labor-heavy % of collections | toward ~1.3% of collections |
The four structural advantages
Paperless
An ambient AI scribe writes the note — no transcription, templating or scribe-labor cost. The same model that documents the visit also drives the code, so documentation and coding are one step, not two.
Cashless / automated RCM
Clean claims on first pass plus automated denial and appeal generation and continuous AR — pushing RCM cost-to-serve toward ~1.3% of collections, versus the human billing shops every incumbent carries.
Shift-left on encounter / coding
The visit is coded correctly at the point of care, to documentation-supported specificity — not under-coded for safety and reworked later. PCP's narrow E/M surface (99213/99214) makes this low-risk and highly automatable.
AI/ML that learns every encounter
Accuracy compounds with volume — coding, denial recovery and AR all improve as the system sees more encounters. No rules-based incumbent gets this flywheel; it is exactly why the margin ramps rather than starting maxed.
See the coding analysis for the primary-care E/M distribution that underpins the capture and margin, and the EMR/RCM deep dive for the full TCO & net-revenue model.
Downside sensitivity — even if we fail by a lot, we still win
Every cell is computed off the base model: MOIC = ARR × (% of plan) × (exit multiple) × 20% ÷ $4M seed, with base ARR = $50.9M and the seed owning 20% (held to exit — no Series A/B dilution). Rows haircut the exit multiple (10× → 4×); columns haircut ARR vs. plan (100% → 50%). The base case is highlighted; the amber cell is a deliberately pessimistic floor. Even 6× on half the plan still returns ~7.6× the seed.
| Exit multiple ↓ / ARR vs plan → | 100% of plan $50.9M ARR |
75% of plan $38.2M ARR |
50% of plan $25.4M ARR |
|---|---|---|---|
| 10× | 25.4×$101.8M · 10× base case | 19.1×$76.3M | 12.7×$50.9M |
| 8× | 20.4×$81.4M | 15.3×$61.1M | 10.2×$40.7M |
| 6× | 15.3×$61.1M · 6× floor | 11.5×$45.8M | 7.6×$30.5M |
| 4× | 10.2×$40.7M | 7.6×$30.5M | 5.1×$20.4M |
Read it this way: the 6× downside floor is 15.3×, with the 10× base case at 25.4×. To fall below ~5× on the seed you would need to simultaneously halve the plan and have the exit compress to 4× ARR — and even that pessimistic corner returns 5.1× ($20.4M). Every other cell returns 7.6× to 25.4×. The seed is structurally protected by how far the company has to miss before the return stops being excellent.
Margin haircut — still strongly EBITDA-positive
Hold revenue at the $50.9M run-rate and instead crush the gross margin. Below-the-line corporate opex (core eng/DevOps + G&A + a lean ~15% external sales motion; ~85% of the market is captive) runs only ~$6.6M/yr, so the company stays strongly EBITDA-positive even at a 60% gross margin — nearly 20 points below plan.
| Gross-margin scenario | Gross profit (on $50.9M) | − Corp opex | Implied EBITDA | EBITDA margin |
|---|---|---|---|---|
| 78% — plan | $39.7M | $6.6M | $33.1M | 65% |
| 70% — haircut | $35.6M | $6.6M | $29.0M | 57% |
| 60% — severe haircut | $30.5M | $6.6M | $23.9M | 47% |
| 50% — collapse | $25.4M | $6.6M | $18.8M | 37% |
Even a 50% gross margin — a near-collapse of the entire thesis — still leaves ~$18.8M of run-rate EBITDA (37% margin). The downside is not "do we make money," it is only "how large is the win."
Illustrative computations. The downside cells are arithmetic sensitivities off the base proforma (ARR $50.9M, 20% seed ownership, $4M seed); they hold all else constant and are not separate forecasts. They show the shape of the returns under stress, not a prediction that any single haircut will occur.
Why a miss doesn't break us: the burn flexes with the market
The cost base isn't committed ahead of the revenue. Outside a small fixed core — core engineering, DevOps and product — we add downstream capacity only after the physicians and practices that pay for it are signed. And because ~85% of the market is captive (partners feed the practices) and the external sales motion is lean (~15%), there is no big sales org to carry ahead of revenue. Burn follows revenue, not the other way around, so the model adjusts to the market in near-real-time.
Slower than plan?
Hiring slows with it. We staff against signed practices, so a soft quarter stretches cash instead of draining it — we're not carrying a team built for revenue that hasn't arrived.
Faster than plan?
We scale into demand we've already won — capacity is added against booked revenue, not a forecast, so growth funds its own ramp.
Tiny fixed floor
Core engineering/DevOps/product plus a lean ~15% external sales motion is the only standing cost — ~85% of the market is captive. Everything downstream — onboarding, support, RCM ops — is variable and demand-triggered.
That's the deeper reason a miss doesn't sink us: it isn't only that the exit math still works at a fraction of plan — it's that the company flexes its spend to whatever the market gives it, so it doesn't burn ahead of the revenue it has actually earned.
On the captive channel: growth depends on Empower / partner networks adopting REV — the single biggest dependency to manage. The lean, demand-triggered cost base is exactly what lets us self-fund through a slower channel instead of burning ahead of it.
On cash: the base plan's thinnest point is ~$911K, around month 38 — right around EBITDA breakeven at month 39. That's a thin but positive cushion — but it stays positive on the $4M seed alone, with no Series A/B. The flex above is what protects it: in a slower scenario we hire and spend later, so the trough doesn't deepen the way a fixed-cost build would. The company that runs out of cash in a downside is the one that staffed ahead of revenue — by design, this one doesn't. (A genuinely faster cert/onboarding slip is the real risk to watch, not demand.)
And we keep what we earn — the tax structure
The run-rate EBITDA above is before tax — and the gap between EBITDA and cash kept is unusually small here. REV is a Texas company with years of planned losses before profit. Between NOL carryforwards, R&D incentives, and Texas having no income tax, the model carries near-zero cash tax for years, then a low-teens effective rate — well under the 21% federal statutory ceiling, and nowhere near the combined rate a California or New York competitor pays.
| Phase | Federal | Texas | Effective cash tax |
|---|---|---|---|
| Build + early growth (losses) | $0 (losses) | $0 (<$2.47M rev) | ~0% |
| First profitable years (NOLs apply) | $0 (NOL shield) | ~0.33% margin | ~0–1% |
| Mature (NOLs exhausted) | ~13–16% effective | ~0.33–0.75% margin | ~14–16% |
Three structural deferments
NOL carryforward
Every dollar of loss in the build and early-growth years offsets future taxable income dollar-for-dollar. Several planned loss years stack into a pool that shields the first profitable years entirely — cash tax stays ~$0 well past breakeven.
R&D incentives
Software development is qualified R&D. R&E expensing and the R&D credit let software companies deduct or credit a large share of spend — a primary reason profitable tech firms post effective rates well below 21%.
Texas domicile
No state corporate or personal income tax — only a franchise/margin tax ($0 under $2.47M revenue, then ~0.33% EZ). A structural edge worth several points of margin versus a high-tax-state competitor.
Mechanism in the model: early losses accumulate into an NOL pool, applied against later positive pre-tax income before any tax; the remainder is taxed at a ~15% blended effective federal rate (21% statutory net of R&D credits) plus the Texas margin tax (~0.33% of revenue, $0 below $2.47M). Net: minimal cash tax for years, modest thereafter.
Illustrative, not tax advice. Effective-rate and franchise-tax assumptions for the proforma; final rates to be confirmed with the company's CPA. Federal effective-rate context: GAO/ITEP show large profitable firms averaging ~16%, with many tech companies far lower after R&D and depreciation incentives.
Scope — this is the primary-care case
Every number here is the independent primary-care case.
The model is built for independent primary care — 1–5 clinician practices running routine established-patient E/M. That is what makes ~78% gross margin defensible: a narrow, repeatable, automatable visit mix (99213 + 99214 dominate) where ambient documentation and AI coding do nearly all the work.
Other specialties and non-ambulatory settings will look different — often lower margin, with more coding complexity (procedures, modifiers, prior auth, facility billing). We are not assuming those economics. REV wins primary care first; specialty and enterprise expansion is upside layered on top of a defended PCP base, not baked into these returns.
Basis for the E/M mix: see the coding analysis →
Sources & footnotes
- athenahealth margins. From athenahealth's last full year as a standalone public company (FY2018, prior to take-private): ~54% non-GAAP gross margin; ~29% adjusted (non-GAAP) EBITDA margin (Q2 28.9% / Q3 29.2%); GAAP operating margin only mid-teens — the latter is after stock-based comp, executive compensation, S&M, R&D, D&A and public-company overhead, so it understates underlying economics. The adjusted-EBITDA line is the apples-to-apples comparison to REV's run-rate EBITDA. Directional benchmark for a scaled, multi-specialty EMR/RCM platform with a large human RCM workforce.
- athenahealth transaction values. Taken private by Veritas Capital and Evergreen Coast Capital for ~$5.7B in 2019; subsequently acquired by Bain Capital and Hellman & Friedman for ~$17B in 2021 — evidence of the durable value the market assigns to EMR/RCM platforms even at incumbent margins.
- REV base figures. From the proforma export: revenue run-rate $50.9M, gross margin ~78%, run-rate EBITDA ~$33.1M ($2.76M/mo × 12), end-state 866 physicians across 346 practices, exit at a 10× multiple → EV $509M, investor proceeds $101.8M, gross MOIC 25.4× on a $4M seed @ 20%, held to exit with no Series A or B (~85% captive market + a lean ~15% external sales motion). Per-provider collections at scale $1,071,000/yr ($89,250/mo) at a 98.5% capture target; Year 1 ~70% of scale (~$750K). Pricing: $595/provider/mo + 4.9% of collections.
- Downside matrix. Illustrative arithmetic off the base model (MOIC = ARR × plan% × multiple × 20% ÷ $4M); margin-haircut row holds revenue at $50.9M and below-gross corporate opex at ~$6.6M/yr. Sensitivities, not separate forecasts.
Related: proforma snapshot · EMR/RCM deep dive · coding analysis · supporting material.